Atlas Trials

A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Clinical trial NCT03800706 · UNKNOWN

Trial details

NCT number
NCT03800706
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Safety and Effectiveness
Start date
2019-03-25
Primary completion
2021-06-30
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.